Author

M. Ramgopal

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety and Efficacy of Doravirine/Islatravir (100 mg/0.25 mg) Once Daily after Islatravir Dose Reduction from 0.75 mg: Week 96 Results from an Open-Label Phase 3 Study in Adults with HIV-1.

BACKGROUND Once-daily doravirine/islatravir (DOR/ISL 100 mg/0.25 mg) demonstrated non-inferior efficacy and comparable safety to continuing prior antiretroviral therapy in two phase 3 studies of virologically suppressed adults with HIV-1. We assessed the safety and efficacy of DOR/ISL (100 mg/0.25 mg) in participants w...

R. Mngqibisa, S. Kassim, Cheryl McDonald et al. · Journal of Acquired Immune D... · 0 citations

Open access Sep 2026

Real-world use and effectiveness of fostemsavir in a US clinical setting: Insights from Trio Health HIV Research Network.

OBJECTIVE To describe real-world patterns of use, virologic and immunologic outcomes and treatment persistence among people with HIV (PWH) initiating fostemsavir (FTR) in a diverse US cohort. DESIGN Retrospective cohort study of adults receiving FTR in clinical practice, stratified by baseline viral suppression statu...

Rick A. Elion, C. Henegar, I. McEwen et al. · HIV Medicine · 0 citations

Open access Sep 2026

Clinical Characteristics, Healthcare Utilization, and Treatment Patterns Among People Living with HIV by Antiretroviral Therapy Use in the USA, 2021–2024

Despite advances in antiretroviral therapy (ART), real-world data remain limited regarding clinical characteristics and healthcare utilization according to ART use among people living with human immunodeficiency virus (PLWH), as well as patterns of ART use in this population. This retrospective cohort study used a US h...

M. Ramgopal, J. Lalezari, C. Huisingh et al. · Infectious Disease and Thera... · 0 citations